BDI BioEnergy Internat Buy

Similar documents
ISRA VISION Neutral

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation

Advanced Vision Techn Buy

Solid preliminary FY 2014 results released. Net asset value increased by 3.5% in H 2014 with difficult trading environment

BUY (previous: BUY) (previous: 77.50)

GOING EAST & ONE YEAR AFTER

Borussia Dortmund GmbH & Co. KGaA

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A

TEMPORARILY NO VALUATION. (previous: not rated)

Electronics Line 3000 Ltd.

HOLD 51,85. (previous: Hold) (previous: 51,65)

Evaluation result Fair value DPS. adj. net. adj. EPS ( )

PA Power Automation AG

SFC Energy AG STRONG GROWTH AND PROFITABILITY AHEAD. FIRST BERLIN Equity Research. Preliminary PRICE TARGET S F

13 May 2016 PNE WIND AG. FIRST BERLIN Equity Research

NOT RATED. (previously Buy) (previously 1.73) adj. net (mln ) DPS ( ) adj. EPS ( )

17 May 2016 ISARIA Wohnbau AG. FIRST BERLIN Equity Research

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following

Buy. Straumann Price CHF (Closing price as of ) Applied disclosures can be found in the appendix

CLERE AG DELISTING & TAKEOVER BID BY MAIN SHAREHOLDER. FIRST BERLIN Equity Research. Delisting & PRICE TARGET C L

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected

PA Power Automation AG

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

Intershop Communications AG

HOLD (previous: BUY) (previous: 68.00)

Neutral (Buy) MLP Price EUR10.30 (Closing price as of ) Applied disclosures can be found in the appendix

18 October 2016 aventron AG. FIRST BERLIN Equity Research

Results Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013

18 November 2016 Energiekontor AG. FIRST BERLIN Equity Research

SABIC Overall strong performance

14 August 2017 PNE WIND AG. FIRST BERLIN Equity Research

Petro Rabigh Shutdown marred Q2 results

PNE WIND AG OFFSHORE PROJECT ATLANTIS I SOLD. FIRST BERLIN Equity Research. Good start to PRICE TARGET P N

20 April 2018 Energiekontor AG. FIRST BERLIN Equity Research

ContextVision. Neutral stance maintained after 3Q. 3Q14 Results analysis November 5 th 2014 Share price: NOK Target: NOK 24.

Daewoo E&C ( KS) WHAT S THE STORY?

7C Solarparken GUIDANCE FOR 2016 INCREASED. FIRST BERLIN Equity Research. Preliminary 2014 PRICE TARGET 2.10

Evaluation result Fair value BUY (prev.: BUY) (prev.: 21.52)

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

27 March 2019 SFC Energy AG. FIRST BERLIN Equity Research. Final SUSTAINABLE MACRO TRENDS SUPPORT FUEL CELL BUSINESS

Yansab Better than expected results

Air France-KLM. Hold TP 6.50 CP 7.59 (Close 21 October 2013) Q3 due 31 October More restructuring needed. Equity Research Quick Bite Preview

Key ratios Sales adj. net

5 September 2016 OTI Greentech AG. FIRST BERLIN Equity Research

2014 E 2015 E 2016 E 2017 E

Leifheit AG. Management Meeting confirms our positive view. Buy (Buy) EUR (60.00 EUR ) BANKHAUS LAMPE // 1 16/02/2016

- 2/7 - Segment Discussion August 05, Segment Discussion. Stock and Valuation

Research Note. Fair Value REIT-AG

Simmtech (222800) Focus on 2H earnings WHAT S THE STORY?

EQUINET INVESTIGATOR

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

ContextVision. Solid 2Q and more details on the contract awaited. August 18 th 2014 Share price: NOK Target: NOK Risk: Medium.

Quiet quarter, attractive valuation

22 November 2017 Energiekontor AG. FIRST BERLIN Equity Research

LUCISANO MEDIA GROUP. New partner for Lucisano. Buy (maintained) Company Update

HAEMATO AG MARKET SHARE WIN IN PARALLEL IMPORT BUSINESS. FIRST BERLIN Equity Research H1/18 PRICE TARGET H A

5 November C Solarparken AG. FIRST BERLIN Equity Research

Financials/Prime Standard

Klaus Kränzle, Please inform yourself of important disclosures and disclaimers in the appendix

Evaluation Result Fair Value BUY (previous: BUY) (previous: 65.50)

Reduced EPS but smart acquisition

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

6 September 2016 aventron AG. FIRST BERLIN Equity Research

ContextVision. Expecting solid results and awaiting progress update on research program

Adler Real Estate AG. Fewer vacancies, more properties. Buy (Buy) EUR (16.50 EUR ) BANKHAUS LAMPE // 1 28/03/2017

HOLD (previous: Hold) (previous: 51.85)

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS

Indygotech Minerals S.A.

Itway (ITW.IM) 1H 08/09 results: once again affected by the crisis June 16, 2009

S-Oil (010950) Healthier revenue structure already reflected in valuations

Buy PT EUR24,00, upside 23%

BUY (previous: BUY) (previous: 72.30) DPS ( ) adj. EPS ( )

Adani Ports & SEZ Rating: Target price: EPS:

Almarai Steady performance

Zain KSA restructuring ensures fresh start

NOW ON APP Research at your finger tips

Dr Reddy s Laboratories

KPN Telecom Operators - Netherlands

14 September 2017 Pharming Group NV. FIRST BERLIN Equity Research. Update. Bloomberg: PHARM NA Return Potential 216.5% ISIN: NL

HOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

All for One Steeb AG August 13, 2013

Saudi Ceramic Expansion plan key growth driver

Key estimate revision. Financial summary. Year

26 October 2017 Energiekontor AG. FIRST BERLIN Equity Research. Update. Bloomberg: EKT GR Return Potential 67.2% ISIN: DE

ad pepper media International N.V.

adesso AG MAY 31, 2012

14 November 2018 M1 Kliniken AG. FIRST BERLIN Equity Research. H1/18 figures &

LG International (001120) Poor 3Q expected to be just a blip WHAT S THE STORY? SUMMARY OF 3Q RESULTS

Table 1. Sum-of-the-parts valuation. EPS Growth

Fila Korea (081660) Widespread growth potential

BURFORD CAPITAL. Financial summary and valuation

adesso AG November 5, 2012

CrucialTec (114120) BUY (Maintain) Company Note. Robust growth to continue. TP: W70,000 (Up)

18 May 2018 Pharming Group NV. FIRST BERLIN Equity Research

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Ma aden Equity infusion will strengthen balance sheet

24 May 2016 Energiekontor AG. FIRST BERLIN Equity Research

18 May 2018 Energiekontor AG. FIRST BERLIN Equity Research

Transcription:

13/08/12 13/10/12 13/12/12 13/02/13 13/04/13 13/06/13 13/08/13 13/10/13 13/12/13 13/02/14 13/04/14 13/06/14 13/08/14 MATELAN Research Update Note Price as of 13/08/14: 10.29 14 August 2014 Company / Sector Fair Value Recommendation BDI BioEnergy Internat. 14.2 Buy Energy: Biofuels (unchanged) (unchanged) Q2 weak but net cash limits the risk Share price performance 40 30 20 10 0 20 16 12 8 4 0 Investment case As indicated, the second quarter shows the impact of the project delays on earnings and cash flow. As the second half should also be affected, we confirm our estimates that we had reduced on July 28 th. However, BDI s current market cap is almost fully covered by the company s net cash position and operating prospects are backed by a EUR70m order book. Against this background we reiterate our Buy rating on the stock. Share data Volume (000, l.s.) Close (EUR, r.s.) Reuters D7I.DE No. of shares (m) 3.80 Daily volume (3m) 3,288 Free float 19.1% Market cap. (m) 39.1 EV (m) n.m. Sales 12-16e 7.7% Valuation 2014e 2015e EV/Sales n.m. n.m. EV/ EBITDA n.m. n.m. EV/EBIT n.m. n.m. PER n.m. 12.9 Div. yield % 1.9% RoCE n.m. 11.3% RoE n.m. 6.0% IMPACT OF PROJECT DELAYS SHOWS IN Q2 As already indicated by preliminary figures, Q2 produced a negative EBIT of EUR-2.2m on EUR4.3m in sales while the company was almost break-even on similar sales in Q1. The major difference to Q1 was a normalisation of material costs and no extraordinary gain. REDUCED ESTIMATES CAN BE CONFIRMED We still believe that the company needs quarterly sales of around EUR8m in order to operate profitably. However, the delay in major projects that has impacted the first half of the year is set to leave its mark on the second half as well. We had already lowered our estimates, which we can confirm at this stage. We also reiterate our fair value of EUR14.2. MARKET CAP BACKED BY NET CASH In contrast to the first quarter, free cash flow turned negative (EUR-3.3m) in Q2. In addition, EUR4.2m was paid to shareholders as dividend. Net cash thus came down to EUR37.1m, i.e. EUR9.8 per share. This equates almost BDI s entire market cap. For additional disclosures please refer to the appendix Analysts Forecasts Hartmut Moers Sales ( m) 29.78 35.45 17.50 40 43.10 Tel.: +49 228 227 99 240 EBITDA ( m) -0.22 3.57-3.10 4.38 4.87 hartmut.moers@matelan.de EBIT ( m) -6.73 2.59-4.50 3.05 3.45 Adj. EPS ( ) -1.16 0.85-0.70 0.80 0.88 Peter Wirtz Dividend ( ) 0 1.10 0 0.20 0.22 Tel.: +49 176 561 63 585 Oper. CF ( m) -6.29 15.45-1.44 4.23 5.23 peter.wirtz@matelan.de Free CF ( m) -8.46 14.96-1.94 3.53 4.43

Sales and EBIT margin 5 2% Adj. EPS and DPS 1.50 4 % 1.00 3 2 % -% 0.50 0-0.50-2% -1.00-3% -1.50 Sales EBIT margin (r.s.) Adj. EPS DPS In EUR Cash Flow RoCE 2 2 2 120% 80% 40% 0% - - - - - -40% -80% -120% Capex Change in NWC Intangibles PPE Cash Earnings Free Cash Flow (r.s.) NWC RoCE (r.s.) Balance Sheet Shareholder structure 9 8 7 6 5 4 3 2 Assets Liabilities Intangibles Tangibles Working Cap. Other Assets Cash Equity Pensions Financial debt Working Cap. Other Liab. 4.0% 2.8% 1.2% 19.6% 72.3% BDI Beteil. VTU Gössler Hammer Free float - 2 -

P & L EURm Sales 29.8 35.4 17.5 4 43.1 Growth 19.0% -50.6% 128.6% 7.8% Material costs / Inv. -17.0-19.7-9.7-22.2-23.9 Gross profit 12.7 15.7 7.8 17.8 19.2 Gross margin 42.8% 44.3% 44.5% 44.5% 44.5% Other operating costs -13.0-12.1-10.9-13.4-14.3 EBITDA -0.2 3.6-3.1 4.4 4.9 Margin -0.7% 10.1% -17.7% 11.0% 11.3% Depreciation -6.5-1.0-1.4-1.3-1.4 Margin -22.6% 7.3% -25.7% 7.6% 8.0% Financial result 1.2 1.3 1.0 1.0 1.0 EBT -5.5 3.8-3.5 4.1 4.5 Taxes 1.1-0.6 0.9-1.0-1.1 Net profit -4.4 3.2-2.7 3.0 3.4 Minorities Net profit a.m. -4.4 3.2-2.7 3.0 3.4 Growth n.m. -182.2% -214.4% 10.3% No of shares 3.8 3.8 3.8 3.8 3.8 EPS -1.16 0.85-0.70 0.80 0.88 Adj. EPS -1.16 0.85-0.70 0.80 0.88 Growth n.m. n.m. -182.2% -214.4% 10.3% Dividend 0 1.10 0 0.20 0.22 Balance Sheet EURm Intangible assets 9.3 8.9 8.6 8.5 8.5 Tangible assets 2.0 1.9 2.0 2.5 2.6 LT financial assets 23.1 2 26.2 26.2 26.2 Other non-current assets 12.1 12.8 13.1 13.1 13.1 Non-current assets 46.5 48.7 49.8 50.2 50.3 Inventories 1.2 0.7 0.7 1.1 1.2 Receivables 12.6 11.4 8.0 12.2 13.1 Cash 12.8 20.1 12.0 14.6 17.7 Other current assets 1.9 0.1 0.1 0.1 Current Assets 28.4 32.3 20.9 28.0 32.2 Total assets 7 80.9 70.6 78.2 82.4 Equity 50.7 53.8 46.9 5 52.6 Minorities Total equity 50.7 53.8 46.9 5 52.6 LT financial liabilities Pension provisions 2.0 2.2 2.4 2.5 2.6 Other LT liabilities 1.0 Non-current liabilities 2.0 2.2 2.4 2.5 3.6 ST financial liabilities Payables & Advances 8.0 10.5 14.5 18.5 19.9 Other ST liabilities 14.4 14.4 6.8 7.2 7.3 Current liabilities 22.3 24.9 21.3 25.7 27.2 Total liabilities 7 80.9 70.6 78.2 83.4 Cash Flow EURm Depreciation 6.5 1.0 1.4 1.3 1.4 Other non-cash items -0.4 8.4-6.7 1.5 1.1 Cash taxes 1.1-0.6 0.9-1.0-1.1 Cash earnings 0.5 11.3-8.9 4.8 4.8 Change in NWC -6.7 4.1 7.4-0.6 0.4 CF from operations -6.3 15.5-1.4 4.2 5.2 Capex -2.2-0.5-0.5-0.7-0.8 Other investm./divestm. CF from investing 2.9-0.5-0.5-0.7-0.8 CF from fin. and other -1.8-7.6-6.2-1.0-1.3 Change in cash -5.2 7.4-8.1 2.6 3.1 Segments and adjusted earnings EURm BioDiesel plants 18.2 27.8 14.0 3 36.5 Fine-vacuum dist. 6.6 7.2 3.0 4.0 BioGas plants 0.5 0.5 1.0 1.6 Sales 29.8 35.4 17.5 4 43.1 Biodiesel plants 0.7 2.0-4.0 2.8 2.9 Magin 3.8% 7.1% -28.6% 8.0% 8.0% Fine-vacuum dist. -0.3 0.3 0.3 0.2 0.4 Margin -4.3% 4.0% % % 8.0% BioGas plants -7.1 0.3-0.8 0.1 0.1 Margin -143.8% 74.7% -16% % 8.0% Margin -22.6% 7.3% -25.7% 7.6% 8.0% Valuation multiples Share price 10.79 7.31 10.29 10.29 10.29 x No of shares (m) 3.8 3.8 3.8 3.8 3.8 Market Capitalisation 41.0 27.8 39.1 39.1 39.1 + Net financial debt -35.8-45.1-38.2-40.8-43.9 + Pension provision 2.0 2.2 2.4 2.5 2.6 + Minorities - Participations -12.1-12.8-13.1-13.1-13.1 Enterprise Value -4.9-27.9-9.8-12.2-15.2 Sales 29.8 35.4 17.5 4 43.1 Adj. EBITDA -0.2 3.6-3.1 4.4 4.9 Adj. Adj. Net profit a.m. -4.4 3.2-2.7 3.0 3.4 EV / Sales -0.2-0.8-0.6-0.3-0.4 EV / EBITDA 22.2-7.8 3.1-2.8-3.1 EV / EBIT 0.7-10.8 2.2-4.0-4.4 PE -9.3 8.6-14.7 12.9 11.7 Key operational indicators Equity ratio 67.6% 66.5% 66.5% 63.9% 63.0% Gearing Asset turnover 0.4 0.4 0.2 0.5 0.5 NWC / sales 19.7% 4.6% -33.3% -13.0% -13.0% Payable days outstanding 97.6 108.2 303.5 168.9 168.8 Receivable days outstandi 154.2 117.9 167.1 111.2 111.2 Fix operating assets 11.4 10.9 10.6 11.0 11.1 NWC 5.9 1.6-5.8-5.2-5.6 Capital employed 17.2 12.5 4.7 5.8 5.4 RoE -8.7% 6.0% -5.7% 6.1% 6.4% RoA -9.0% 3.2% -6.4% 3.9% 4.2% RoCE -39.1% 20.7% -9% 52.8% 63.3% Gross margin 42.8% 44.3% 44.5% 44.5% 44.5% EBITDA margin -0.7% 10.1% -17.7% 11.0% 11.3% EBIT margin -22.6% 7.3% -25.7% 7.6% 8.0% Net profit margin -14.8% 9.1% -15.2% 7.6% 7.8% - 3 -

ADDITIONAL DISCLOSURES This report has been prepared by Matelan Research GmbH, Koblenzer Str. 79, 53177 Bonn. All rights are reserved. Copyrights and database rights protection exists in this publication. It may not be reproduced or redistributed without prior express permission of Matelan. (1) Analyst certification The analysts responsible for the content of this research report hereby certify that (1) all views expressed in this report accurately reflect their views about any and all of the subject securities or issuers and (2) no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or view(s) of this report. Matelan may have sent extracts of this research report to the subject company for the purpose of verifying factual accuracy. The information provided by the latter was taken into consideration in the report. However, this entailed no change of the assessment. (2) Disclosures about potential conflicts of interest Matelan Research GmbH has/will receive(d) compensation for research and advisory services provided in the current calendar year from the company under review. (3) Rating definitions Security firms use a variety of rating terms and systems. Investors should carefully read the definitions of the rating system used in each research report. In addition, since the research report contains more complete information concerning analyst s views, investors should carefully read the entire research report and not infer its contents from the ratings alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor s decision to buy or sell a stock should depend on individual circumstances (such as the investor s existing holdings) and other considerations. MATELAN Research GmbH uses an absolute rating system, which varies considerably from relative rating systems (such as Overweight, Equal Weight or Underweight ). Stock ratings are defined as follows: Strong Buy: In the next 6 to 12 months, we expect a potential absolute change in value of over 20% with high forecast certainty. Buy: In the next 6 to 12 months, we expect a potential absolute change in value of more than 10%. Neutral: In the next 6 to 12 months, we expect a potential absolute change in value of over 0% up to a maximum of 10%. Reduce: In the next 6 to 12 months, we expect a potential absolute negative change in value of up to -10%. Sell: In the next 6 to 12 months, we expect a potential absolute negative change in value of over -10 % with high forecast certainty. The change in stock price results from the difference between the current share price and the analyst s performance expectations, which are generally based on a fair value calculation performed on the basis of a discounted cash flow model and a key comparison analysis but can also consider other effects such as market sentiment. (4) Rating distribution Stock ratings within the coverage universe of MATELAN Research GmbH as of the publication date of this report are distributed as follows: Strong Buy: 9.1% Buy: 45.5% Neutral: 45.5% Reduce: % Sell: % (5) Recommendation history Stock ratings for the company covered in this report have developed as follows: BDI Date Rating 15/11/13 Buy 16/02/11 Neutral - 4 -

(6) Additional information for clients in Germany and other countries This research report has been produced in Germany. It was approved and distributed by MATELAN Research GmbH, which is supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). Laws and regulations in other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. In particular, this document may not be distributed in the United States, Canada, Australia or Japan or to any U.S. person. DISCLAIMER This research publication has been prepared by MATELAN analysts based on publicly available data that is believed to be accurate and complete. While reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, MATELAN provides no representation or warranty in relation to its accuracy, completeness or reliability. Possible errors or incompleteness of the information do not constitute grounds for liability, either with regard to indirect or to direct or consequential damages. In particular, MATELAN is not liable for the statements, plans or other details contained in the information concerning the examined companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Neither MATELAN nor its employees are liable for the accuracy and completeness of the statements, estimates and conclusions derived from the information contained in this report. To the extent this research report is being transmitted in connection with an existing contractual relationship, e.g. financial advisory or similar services, the liability of MATELAN shall be restricted to gross negligence and wilful misconduct. In any case, the liability of MATELAN is limited to typical, foreseeable damages and liability for any indirect damages is excluded. This report does not constitute an offer to sell, or a solicitation of an offer to purchase, any security. MATELAN may perform services to other companies mentioned in this report. Directors or employees of MATELAN may serve on the board of directors of companies mentioned in this report. Any opinions contained herein are subject to change without notice. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. MATELAN does not accept any liability for any loss or damage out of the use of all or any part of this report. Additional information will be made available upon request. Past performance is not necessarily indicative of future results. Investors should make their own investment decisions without relying on this publication. Only investors with sufficient knowledge and experience in financial matters to evaluate the merits and risks should consider an investment in any issuers or market discussed herein and other persons should not take any action on the basis of this publication. Any investments referred to herein may involve significant risk, are not necessarily available in all jurisdictions, may be illiquid and not be suitable for all investors. The price of securities may decrease or increase and as a result investors may lose the amount originally invested. Changes in exchange rates may also cause the value of investments to decrease or increase. Any documents or information we provide is solely for informational purposes and directed only to persons we reasonably believe to be investment professionals. All such communications and any activity to which they relate are available only to such investment professionals; any activity arising from such communications will only be carried out with investment professionals. Persons who do not have professional experience in matters relating to investments shout not rely upon such communications. CONTACT DATA For further information please contact: Matelan Research GmbH Koblenzer Straße 79 53177 Bonn www.matelan.de Head Analyst: Hartmut Moers Tel: +49 228 227 99 240 e-mail: hartmut.moers@matelan.de - 5 -